Results 21 to 30 of about 41,565 (267)
Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis [PDF]
, 2005 Previous studies showed that mitoxantrone can reduce disability progression in patients with multiple sclerosis (MS). There is, however, concern that it may cause irreversible cardiomyopathy with reduced left ventricular (LV) ejection fraction (EF) and ...
Zingler, V. C. +6 more
core +1 more source
Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 [PDF]
, 2010 This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düsseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the
Hohlfeld, Reinhard +2 more
core +1 more source
Italian Journal of Pediatrics, 2021 Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women ...
Elisabetta Godano +8 more
doaj +1 more source
Genomic regions associated with multiple sclerosis are active in B cells. [PDF]
, 2012 More than 50 genomic regions have now been shown to influence the risk of multiple sclerosis (MS). However, the mechanisms of action, and the cell types in which these associated variants act at the molecular level remain largely unknown.
Giulio Disanto +32 more
core +1 more source
Prevalence of sexual disorders in relapsing-remitting multiple sclerosis patients depending on various risk factors [PDF]
Romanian Journal of Medical PracticeObjective. Multiple sclerosis is a perilous, disabling, physically as well as mentally, demyelinating disease of the central nervous system. This work aims to evaluate prevalence of sexual dysfunctions and their correspondence with non- and disease ...
Tetiana Odintsova, Oksana Kopchak
doaj +1 more source
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019 Background Disease-modifying therapies benefit individuals with relapsing forms of multiple sclerosis, but their utility remains unclear for those without relapses.
Sarah L Minden +5 more
doaj +1 more source
Arquivos de Neuro-Psiquiatria, 2011 Cognitive impairment is a symptom of multiple sclerosis (MS). Different clinical forms of multiple sclerosis have different cognitive profiles, according to findings of previous studies which used extensive batteries of neuropsychological tests ...
Dóra-Neide Rodrigues +4 more
doaj +1 more source
Current management of relapsing‐remitting multiple sclerosis [PDF]
Internal Medicine Journal, 2014 AbstractMultiple sclerosis was without effective disease‐modifying therapy for many years. The introduction of the injectable therapies (interferon and glatiramer acetate) some 20 years ago was considered a major advance. Recent years have heralded a revolution in treatment options with the introduction of intravenous natalizumab and, even more ...
L, Sedal, I B, Wilson, E A, McDonald
openaire +2 more sources
Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018 Background Disease-modifying therapies are thought to reduce the conversion rate to secondary progressive multiple sclerosis. Objective To explore the rate, chronology, and contributing factors of conversion to the progressive phase in treated relapsing ...
Francisco Coret +9 more
doaj +1 more source
Cognition and cognitive rehabilitation in adult and juvenile patients with multiple sclerosis [PDF]
, 2015 : Multiple sclerosis (MS) is accompanied by cognitive deficits in half of adult patients and in one third of children. These deficits have a serious impact on daily functioning of patients and may influence the ability to achieve educational goals and ...
Hubacher, Martina
core +1 more source